Syndax 珍 | --- | --- | |-------|--------------------------| | | Dose: 1mg/kg q2wk | | | n= 23 patients | | | Primary endpoint: ORR* | | | (2014 NIH GVHD criteria) | KPS at enrollment, median (range) 80 (60, 100) 80 (60, 90) 80 (60, 100) • No evidence of end-organ damage, myositis/pancreatitis with enzyme elevations 52% FIBROSIS CSF-1R Circulating Monocyte CSF-1 Circulating Monocyte Macrophage Tissue Fibroblasts Collagen CSF-1R CSF-1R CSF-1 Circulating Monocyte Blood vessel CSF-1R M2 macrophage 17 Myeloablat ...

Revumenib Data Update Call with Dr. Ghayas Issa and Dr. Eytan Stein Syndax 參 DECEMBER 11TH, 2022 – ASH ANNUAL MEETING Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. All st ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 3Q22 INVESTOR PRESENTATION – NOVEMBER 3, 2022 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identif ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Briggs Morrison - President and Head, R&D Keith Goldan - Chief Financial Officer Conference Call Participants Philip Nadeau - Cowen Kalpit Patel - B Riley Securities Madhu Kumar - Goldman Sachs Ashiq Mubarack - Citi Peter Lawson - Barclays Joel Beatty - Baird Operator Good day, everyone and welcome to t ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 (781) 419-1400 (Registrant's Telephone Number, Including Area Code) or Securities registered pursuant to Section 12(b) of the Act: ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Sharon Klahre - Head, Investor Relations Michael Metzger - Chief Executive Officer Briggs Morrison - President and Head, R&D Keith Goldan - Chief Financial Officer Anjali Ganguli - Chief Business Officer Conference Call Participants Phil Nadeau - Cowen & Company Kalpit Patel - B. Riley Securities Ashiq Mubarack - Citi Joel Beatty - Baird Peter Lawson - Barclays Operator Good day everyo ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax 參 2Q22 EARNINGS PRESENTATION – AUGUST 8, 2022 Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37708 Syndax Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in Its Charter) Delaware 32-0162505 (State or Other Ju ...

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Maghan Meyers - Vice President, Argot Partners Michael Metzger - Chief Executive Officer Briggs Morrison - President & Head, R&D Alex Nolte - Chief Accounting Officer Peter Ordentlich - Chief Scientific Officer Conference Call Participants Madhu Kumar - Goldman Sachs Phil Nadeau - Cowen & Company Bert Hazlett - BTIG Ashiq Mubarack - Citigroup Joel Beaty - Baird Peter Lawson - Barclays Oper ...

Determined to realize a future in which people with cancer live longer and better than ever before Syndax §> 1Q22 EARNINGS PRESENTATION Forward-looking statements disclosure This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking ...